Profile
RGC ZTS HLN TAK TEVA ITCI
Company Name Regencell Bioscience Holdings Limited Zoetis Inc. Haleon plc Takeda Pharmaceutical Company Limited Teva Pharmaceutical Industries Limited Intra-Cellular Therapies, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $411.21M $70.23B $48.44B $45.27B $19.40B $14.05B
Employees 0.01K 13.80K 24.56K 49.28K 33.89K 0.86K
CEO Mr. Yat-Gai Au Ms. Kristin C. Peck Mr. Brian James McNamara Mr. Christophe Weber Mr. Richard D. Francis Dr. Sharon Mates Ph.D.
Ratings
Trading
RGC ZTS HLN TAK TEVA ITCI
Last Close $366.01 $159.27 $10.74 $14.36 $16.93 $131.87
High 52 $366.01 $196.48 $10.77 $15.37 $22.77 $131.91
Low 52 $3.2 $144.45 $8.24 $12.6 $12.82 $64.96
Price vs. 52 Week High 0 % -18.94 % -0.28 % -6.57 % -25.65 % -0.03 %
Price vs. 52 Week Low 11337.8 % 10.26 % 30.34 % 13.97 % 32.06 % 103 %
Total Return
RGC ZTS HLN TAK TEVA ITCI
1 Month Return 908.85 % 6.58 % 6.76 % 3.46 % 25.78 % 0 %
3 Month Return 9686.36 % -8.4 % 8.92 % 8.3 % 3.61 % 3.05 %
6 Month Return 5682.15 % -8.44 % 15.73 % 6.06 % -1.05 % 49.02 %
9 Month Return 3085.47 % -13.35 % 10.49 % 3.68 % -0.88 % 76.06 %
YTD Return 7309.11 % -2.25 % 12.58 % 8.46 % -23.19 % 57.89 %
1 Year Return 6482.91 % -5.78 % 30.34 % 8.38 % 4.18 % 103 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
RGC ZTS HLN TAK TEVA ITCI
Dividend Yield Percentage (TTM) - 1.18 % 0.02 % 4.63 % - -
Dividend Paid and Capex Coverage Ration (TTM) - 2.05 % - 1.76 % 2.5 % -227.26 %
Dividend Per Share (TTM) - 1.86 % 0.07 % 196 % - -
Payout Ratio (TTM) - 31.62 % - 145.09 % - -
Profitability
RGC ZTS HLN TAK TEVA ITCI
Gross Profit Margin TTM - 69.85 % 61.52 % 54.74 % 48.74 % 91.63 %
Return on Assets TTM -26.51 % 17.46 % 4.2 % 1.38 % -4.17 % -5.46 %
Return on Equity TTM -25.23 % 49.65 % 8.73 % 2.83 % -26.15 % -7.4 %
Return on Capital Employed TTM -29.44 % 31.33 % 7.74 % 3.62 % -1.14 % -10.05 %
Net Income Per EBT TTM 102.65 % 79.35 % 75.5 % 89.75 % 127.75 % 100.64 %
EBT Per Ebit TTM 89.79 % 92.36 % 86.58 % 49.18 % 423.43 % 63.57 %
EBIT Per Revenue TTM - 36.65 % 19.64 % 10.3 % -1.83 % -17.15 %
Cash Flow To Debt Ratio TTM - 43.79 % - 22.2 % 6.9 % -430.93 %
Receivables Turnover TTM - 7.03 5.9 6.23 5.41 4.09
Payables Turnover TTM - 6.45 2.19 4.5 3.85 2.18
Inventory Turnover TTM - 1.21 3.63 1.66 2.82 2.17
Fixed Asset Turnover TTM - 256.4 % 584.75 % 226.93 % 334.34 % 4569.25 %
Asset Turnover TTM - 65.01 % 32.73 % 30.31 % 42.07 % 49.79 %
Operating Cash Flow Per Share TTM - 6.55 - 677.91 1.1 -0.71
Free Cash Flow Per Share TTM - 5.1 - 483.45 0.66 -0.71
Cash Per Share TTM 61.18 % 440.62 % 24.05 % 33229.49 % 291.26 % 970.67 %
Operating Cash Flow Sales Ratio TTM - 31.9 % - 23.47 % 7.54 % -10.75 %
Free Cash Flow Operating Cash Flow Ratio TTM - 77.82 % - 71.32 % 60.06 % 100.44 %
Cash Flow Coverage Ratios TTM - 43.79 % - 22.2 % 6.9 % -430.93 %
Price To Free Cash Flows Ratio TTM - 30.56 - 8.69 26.32 -191.12
Price To Operating Cash Flows Ratio TTM - 24.02 - 6.25 15.63 -185.85
Price Cash Flow Ratio TTM - 24.02 - 6.25 15.63 -185.85
Income Statement (TTM)
RGC ZTS HLN TAK TEVA ITCI
Revenue $0B $9.26B $11.23B $4263.76B $16.54B $0.68B
Gross Profit $-0B $6.54B $6.95B $2832.26B $8.06B $0.62B
Gross Profit Ratio 0% 70.62% 61.85% 66.43% 48.74% 91.63%
EBITDA $-0B $3.87B $2.51B $874.6B $0.72B $-0.12B
Net Income $-0B $2.49B $1.44B $144.07B $-1.64B $-0.07B
EPS Diluted -0.33 5.47 0.32 45.58 -1.45 -0.72
Balance Sheet (MRQ)
RGC ZTS HLN TAK TEVA ITCI
Long Term Debt $0B $5.39B $8.54B $5029.93B $16B $0.01B
Total Liabilities $0B $9.47B $18.09B $7834.79B $33.61B $0.22B
Total Equity $0.01B $4.77B $16.22B $7274.01B $5.73B $1.15B
Total Investments $0.01B $0B $0.08B $445.7B $0B $0.69B
Total Debt $0B $6.74B $10.1B $4843.75B $18.08B $0.02B
Total Assets $0.01B $14.24B $34.32B $15108.79B $39.33B $1.37B
Cash Flow Statement (TTM)
RGC ZTS HLN TAK TEVA ITCI
Net Income $-0B $2.5B $1.44B $144.07B $-1.96B $-0.07B
Inventory $0B $-0.04B $0.22B $-115.74B $0.17B $-0.01B
Dividends Paid $0B $-0.79B $-0.57B $-287.19B $0B $0B
Operating Cash Flow $-0B $2.95B $2.3B $716.34B $1.25B $-0.07B
Capital Expenditure $-0B $-0.66B $-0.25B $-480.73B $-0.5B $-0B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.85
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.16
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 9.68
ALVOW Alvotech 1.79
AMPH Amphastar Pharmaceuticals, Inc. 24.11
AMRX Amneal Pharmaceuticals, Inc. 7.41
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 66.3
APUS Apimeds Pharmaceuticals US, Inc 0.00001
AQST Aquestive Therapeutics, Inc. 2.79
ASRT Assertio Holdings, Inc. 0.61
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 9.39
Unlock